Clinical Trials
95 trialsClinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Melanoma
National Institutes of Health Clinical Center (CC)
Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors
M.D. Anderson Cancer Center
Liquid Biopsy Multi-Omics and Biomarker Development in Melanoma
Xijing Hospital
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Alliance for Clinical Trials in Oncology
LONGEVITI
University of Alberta
SHERLOCK
University Health Network, Toronto
iCaRe2
University of Nebraska
Project: Every Child for Younger Patients With Cancer
Children's Oncology Group
Quality of Life, Lifestyle, and Psychosocial Factors in Patients With Melanoma
M.D. Anderson Cancer Center
Evaluation for NCI Surgery Branch Clinical Research Protocols
National Institutes of Health Clinical Center (CC)
DP-04
AstraZeneca
Sub-topic Four: Clinical Translation of Original Radioactive Drugs for Precision Diagnosis and Treatment of Gastrointestinal Tumors -Clinical Application Value of PET Imaging Targeting LRRC15 in Malignant Tumors
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
CER
Cancer Support Community, Research and Training Institute, Philadelphia
SJFAMILY
St. Jude Children's Research Hospital
Well-Being and Health-Related Quality of Life in Melanoma Patients During COVID-19 Pandemic
M.D. Anderson Cancer Center
HELIOPREDICT
Nantes University Hospital
COSMIC
Wake Forest University Health Sciences
PRO-ACTIVE
Fondazione del Piemonte per l'Oncologia
Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome
Ohio State University
Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program
M.D. Anderson Cancer Center
Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors
Washington University School of Medicine
A Storage Facility for Tissues Obtained From Patients With Malignant Melanoma
Ohio State University Comprehensive Cancer Center
Digital Remote Monitoring of Immune Checkpoint Inhibitor Therapy Induced Toxicity Using the Vigilant App
Mayo Clinic
IMPACT
Peter MacCallum Cancer Centre, Australia
Effects of Anti-PD1 Adjuvant Checkpoint Blockade Immunotherapy on Atypical/Dysplastic Nevi
University of Pittsburgh
Correlating Early FDG PET/CT and ctDNA in Immune Checkpoint Inhibitor (ICI)-Treated Melanoma Patients
University of Wisconsin, Madison
SCORE
Natera, Inc.
RPx
Replimune, Inc.
ELEPHAS-05
Elephas
Evaluation of Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types
Mayo Clinic
IMM
University Hospital, Strasbourg, France
MELA_2025
Ente Ospedaliero Ospedali Galliera
Mesur
University of Modena and Reggio Emilia
Liquid Biomarker Study in Melanoma and Non-Melanoma Skin Cancers
University of Wisconsin, Madison
Prospective Collection of Clinical Data and Human Body Material (HBM) of Cutaneous Melanoma and Non Melanoma Patients. Biobank Huidkanker
Universitaire Ziekenhuizen KU Leuven
Reflectance Confocal Microscopy and Molecular Correlation in Atypical Melanocytic Lesions
University of Modena and Reggio Emilia
LIBERATE
University Health Network, Toronto
MELpreserv
Assistance Publique Hopitaux De Marseille
Molecular Analysis of Childhood and Adolescent Melanocytic Lesions
St. Jude Children's Research Hospital
Symptoms of Immune Checkpoint Inhibitor Therapy in Cutaneous Melanoma
University of California, San Francisco
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Massive Bio, Inc.
Skin Cancer
Nuvana Healthcare LTD
Storage and Research Use of Human Bio-specimens From Melanoma Patients and Clinical Testing for Assignment of Treatment
Vanderbilt-Ingram Cancer Center
PIP-PREDICT
Melanoma Institute Australia
Observational Study of Iris Tumors
Oregon Health and Science University
MELAFERT: Impact of Adjuvant Therapy on FERTility in Patients With Resected MELAnoma at High Risk of Relapse.
Intergruppo Melanoma Italiano
SOCRATES
Monash University
ORACLE
Guardant Health, Inc.
Pan-tumor MRD Study
Paradigm Health
RIC-Mel
Nantes University Hospital